| Abstract | Cilj istraživanja: Cilj ovoga istraživanja bio je usporediti serumske koncentracije urotenzina-II između bolesnika s primarnom hipertenzijom i zdravih kontrolnih ispitanika te ustanoviti moguću povezanost između serumskih koncentracija urotenzina-II i prosječnog 24-satnog dijastoličkoga krvnog tlaka, arterijske krutosti i postotka tjelesne masti.
Ispitanici i postupci: Osmišljena kao presječno istraživanje, ova studija obuhvatila je 50 zdravih ispitanika i 50 bolesnika s primarnom hipertenzijom te izvedena na Katedri za patofiziologiju i Zavodu za integrativnu fiziologiju Medicinskog fakulteta Sveučilišta u Splitu u razdoblju od siječnja 2022. do siječnja 2023. godine. Nakon anamneze i fizikalnog pregleda, svim ispitanicima obavljena su antropometrijska mjerenja, postavljen uređaj za 24-satno mjerenje tlaka te uzet uzorak krvi iz vene za analizu.
Rezultati: Dokazana je povišena serumska koncentracija urotenzina-II u bolesnika s primarnom hipertenzijom u odnosu na zdrave kontrole (3,4 ± 1,6 ng/mL vs. 2,7 ± 1,2 ng/mL, P = 0,021). Međutim, serumske koncentracije urotenzina-II nisu se razlikovale između ispitanika s većom (BMI ≥ 30 kg/m2) i manjom tjelesnom masom (BMI < 30 kg/m2) (3,5 ± 1,8 ng/mL vs. 3,4 ± 1,7 ng/mL, P = 0,644). U drugom dijelu istraživanja, utvrđena je pozitivna korelacija između serumskih koncentracija urotenzina-II i BMI-ja (r = 0,188, P = 0,024) te dijastoličkog arterijskog tlaka (r = 0,342, P < 0,001). S druge strane, nije utvrđena statistički značajna povezanost između serumskih koncentracija urotenzina-II i dobi, postotka tjelesne masti, ukupnog kolesterola i brzine pulsnog vala (mjera arterijske krutosti).
Zaključci: Istraživanje je dokazalo postojanje uloge urotenzina-II u primarnoj hipertenziji te povezanost serumskih koncentracija urotenzina-II i prosječnoga 24-satnog dijastoličkog tlaka. Povezanost serumskih koncentracija urotenzina-II, mjera arterijske krutosti i postotka tjelesne masti nije pronađena. |
| Abstract (english) | Objectives: The aim of this research was to compare serum concentrations of urotensin-II between patients with primary hypertension and healthy control subjects and to establish a possible correlation between serum concentrations of urotensin-II and average 24-hour diastolic blood pressure, arterial stiffness and body fat percentage.
Subjects and methods: This cross-sectional study included 50 healthy subjects and 50 patients with primary hypertension and was conducted at the Department of Pathophysiology and the Department of Integrative Physiology of the University of Split School of Medicine in the period from January 2022 to January 2023. After the anamnesis and physical examination, anthropometric measurements were performed on all subjects, a device for 24-hour blood pressure measurement was installed, and a blood sample was taken for analysis.
Results: Elevated serum concentration of urotensin-II was demonstrated in patients with primary hypertension compared to healthy controls (3.4 ± 1.6 ng/mL vs. 2.7 ± 1.2 ng/mL, P = 0.021). However, serum concentrations of urotensin-II did not differ between subjects with higher (BMI ≥ 30 kg/m2) and lower body mass (BMI < 30 kg/m2) (3.5 ± 1.8 ng/mL vs. 3.4 ± 1.7 ng/mL, P = 0.644). In the second part of the study, a positive correlation was found between serum concentrations of urotensin-II and BMI (r = 0.188, P = 0.024) and diastolic arterial pressure (r = 0.342, P < 0.001). No statistically significant association was found between serum concentrations of urotensin-II and age, body fat percentage, total cholesterol and pulse wave velocity (measure of arterial stiffness).
Conclusions: The research proved the existence of the role of urotensin-II in primary hypertension and the connection between serum concentrations of urotensin-II and average 24-hour diastolic pressure. No association was found between serum concentrations of urotensin-II, measures of arterial stiffness and body fat percentage. |
